{"analyses":[{"ciLowerLimit":"-4.66","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"6.51","estimateComment":"95% CI for difference in rates were constructed using Anderson-Hauck method.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7169","paramType":"Difference in Response Rates","paramValue":"0.93","statisticalComment":"P-value was assessed using CMH test stratified by the IvRS randomization stratification factors.","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0"},{"groupId":"OG001","value":"70.4"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"7.9"}]}],"title":"CRi"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.2"},{"groupId":"OG001","value":"13.4"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"0.5"}]}],"title":"SD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"0.5"}]}],"title":"PD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"216"}],"units":"Participants"}],"description":"CR: peripheral blood lymphocytes below 4x10\\^9/L, absence of lymphadenopathy by physical examination and CT scan, no hepatomegaly or splenomegaly, absence of disease or constitutional symptoms, blood counts of neutrophils \\>1.5\\*10\\^9/L, platelets \\>100\\*10\\^9/L and hemoglobin \\>110 g/L, bone marrow at least normocellular for age without clonal infiltrate (except for Cri). PR: any two for at least 2 months: \\>/= 50% decrease in peripheral blood lymphocyte count from the pretreatment value, \\>/=50% reduction in lymphadenopathy, \\>/=50% reduction of liver and/or spleen enlargement, and at least one of the following blood counts: neutrophils \\>1.5\\*10\\^9/L, platelets \\>100\\*10\\^9/L and hemoglobin \\>110 g/L. PD: lymphadenopathy, \\>=50% increase in liver or spleen size, \\>=50% increase in lymphocyte count, transformation to a more aggressive histology or occurrence of cytopenia. SD: a non-response and used to characterize participants who did not achieve a CR or a PR, and who have not exhibited PD.","groups":[{"description":"Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.","id":"OG000","title":"Obinutuzumab + Chlorambucil"},{"description":"Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.","id":"OG001","title":"Obinutuzumab + Venetoclax"}],"paramType":"NUMBER","populationDescription":"ITT population was defined as all randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline up to the completion of treatment assessment 3 months after treatment completion (up to approximately 15 months)","title":"Percentage of Participants By Best Response Achieved (CR, CRi, PR, Stable Disease (SD), or PD)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}